Xvivo Perfusion ABXVIPF -1.32%91 3-Year EBITDA Growth Rate is 17.30% as of Mar. 2026, which is 7% above its 10-year median of 16.15. GuruFocus rates XVIPF with a GF Score™ of 91/100 and a GF Value™ of $42.02 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 696 Medical Devices & Instruments companies, Xvivo Perfusion AB ranks better than 62.79% on this metric.
During the past 12 months, Xvivo Perfusion AB's average EBITDA Per Share Growth Rate was -2.00% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 17.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Xvivo Perfusion AB was 88.90% per year. The lowest was 1.00% per year. And the median was 16.15% per year.
Xvivo Perfusion AB (OTCPK:XVIPF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Xvivo Perfusion AB 3-Year EBITDA Growth Rate Related Terms
XVIPF vs ABT, SYK, MDT: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Xvivo Perfusion AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xvivo Perfusion AB 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Xvivo Perfusion AB's 3-Year EBITDA Growth Rate falls into.
Xvivo Perfusion AB 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 17.30% mean?
Xvivo Perfusion AB (XVIPF) has a 3-Year EBITDA Growth Rate of 17.30% as of Mar. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Xvivo Perfusion AB and its competitors. This is near median its historical median of 16.15. Over the past decade, Xvivo Perfusion AB's 3-Year EBITDA Growth Rate has ranged from 1.00 to 88.90. According to the industry distribution chart, Xvivo Perfusion AB ranks #259 out of 696 companies in the Medical Devices & Instruments industry, placing it in the top 37.2%.
Is Xvivo Perfusion AB's 3-Year EBITDA Growth Rate too high?
Xvivo Perfusion AB's current 3-Year EBITDA Growth Rate of 17.30% is near median its 10-year median of 16.15. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 88.90. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.80. Xvivo Perfusion AB's value of 17.30% is 121.8% above this industry median. Based on the distribution chart, Xvivo Perfusion AB ranks #259 out of 696 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Xvivo Perfusion AB has a GF Score™ of 91/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's 3-Year EBITDA Growth Rate compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Xvivo Perfusion AB ranks #259 out of 696 companies for 3-Year EBITDA Growth Rate. This puts Xvivo Perfusion AB in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 7.80. Xvivo Perfusion AB's value of 17.30% is 121.8% above this benchmark. Historically, Xvivo Perfusion AB's own 3-Year EBITDA Growth Rate has ranged from 1.00 to 88.90 over the past decade. While the company's 10-year median is 16.15 vs. the industry median of 7.80, Xvivo Perfusion AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.80, based on 696 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xvivo Perfusion AB's current 3-Year EBITDA Growth Rate of 17.30% is 121.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Xvivo Perfusion AB and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xvivo Perfusion AB's current 3-Year EBITDA Growth Rate is 17.30%, which is near median its own 10-year median of 16.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (XVIPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $42.02, compared to a current price of $29.00 — trading 31% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 17.30%, which is near median its 10-year median of 16.15 and 121.8% above the Medical Devices & Instruments industry median of 7.80. Xvivo Perfusion AB's overall GF Score™ is 91/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Xvivo Perfusion AB (XVIPF), the current 3-Year EBITDA Growth Rate is 17.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xvivo Perfusion AB (XVIPF) Overvalued in 2026?
Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued.
The current stock price of $29.00 is trading 31% below its estimated GF Value™ of $42.02.
GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.
Key valuation signals for XVIPF:
3-Year EBITDA Growth Rate: 17.30% (near median its 10-year median of 16.15)
GF Value™: $42.02 vs. price of $29.00 (31% below fair value)
Industry Position: 121.8% above the Medical Devices & Instruments median (#259 of 696)
No single metric tells the full story. See the XVIPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
91GF Score
Get the complete analysis for XVIPF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XVIPF has been successfully added to your 